FilingSEC EDGAR8-K
C4 Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Updates
· SEC accepted
StageClinical stage
Filing content
The company reported Q3 revenue of $8.5 million and a net loss of $21.8 million, while providing updates on the MOMENTUM trial and confirming cash runway through the end of 2028.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…